

Comprehensive Insights of the Global Tremfya Market: Key Drivers, Trends, Growth Opportunities, and Forecast for 2034

*Updated 2025 Market Reports Released:
Trends, Forecasts to 2034 – Early
Purchase Your Competitive Edge Today!*

LONDON, GREATER LONDON, UNITED KINGDOM, February 10, 2025

[/EINPresswire.com/](https://www.einpresswire.com/) -- The Tremfya market has witnessed considerable

growth over recent years. The market

size was \$XX million in 2024 and is predicted to reach \$XX million in 2025, reflecting a compound annual growth rate CAGR of XX%. This extraordinary growth in the historic period can be attributed to the rising prevalence of psoriasis and psoriatic arthritis, accompanied by an increasing focus on targeted therapies, rising healthcare investments, a growing number of specialty clinics, and increased adoption of biologics in dermatology and rheumatology.



What is the anticipated growth rate and market size of the [global Tremfya market](#)?

The [Tremfya market size](#) is expected to see a compound annual growth rate FCAGR of XX% in the coming years. It is forecast to grow to \$XX million in 2029. This growth in the forecast period can be attributed to increasing healthcare infrastructure, rising adoption of point-of-care testing, increasing investment in healthcare research, and a growing focus on precision medicine. Major trends in the forecast period include advancements in treatment modalities, personalized medicine approaches, technological integration in patient monitoring, the integration of artificial intelligence AI, and advancements in injection devices.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp>

What is driving the growth of the Tremfya market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the Tremfya market moving forward. Autoimmune diseases refer to conditions where the immune system mistakenly attacks its cells, tissues, or organs as foreign invaders. IL-23, targeted by

Tremfya, a monoclonal antibody, helps manage autoimmune diseases by modulating the immune system's overactive response, reducing inflammation, and offering symptom relief in conditions such as psoriasis and psoriatic arthritis. The continuing increase in autoimmune diseases, driven by genetic predisposition, environmental triggers, lifestyle changes, heightened awareness, and improved diagnostic capabilities, is driving growth in the Tremfya market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report>

Who are the key operatives in the Tremfya market?

A major player operating in the Tremfya market is Johnson & Johnson. Keeping abreast with competitors forms a vital aspect of market strategy in any field, and the Tremfya market is no exception.

What are the emerging trends in the Tremfya market?

Regulatory approvals to broaden patient base and market potential have emerged as a key trend in the Tremfya market. Gaining such approvals allows the drug to be marketed for explicit uses after verifying its safety, efficacy, and quality. For instance, in September 2024, Johnson & Johnson received FDA approval for TREMFYA guselkumab for the treatment of adults with moderately to severely active ulcerative colitis, establishing it as the inaugural dual-acting interleukin-23 inhibitor approved for this condition.

How is the global Tremfya Market segmented?

The Tremfya market is segmented:

- 1 By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA
- 2 By Formulation: Subcutaneous Injection; Intravenous Infusion
- 3 By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
- 4 By End User: Adult Patients; Geriatric Patients

What does the regional outlook look like for the Tremfya Market?

In 2024, North America was the largest region in the Tremfya market. This report provides an overview of all regions included in the Tremfya market report, encompassing Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Inflammatory Bowel Disease Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report>

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report>

Anti-Inflammatory Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 15000+ reports from 27 industries, spanning 60+ geographies. Armed with 1,500,000 datasets, these reports draw on extensive secondary research, and exclusive insights from interviews with industry leaders, providing valuable in-depth insights into potential opportunities and strategies. This affords you the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxlCpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/783894216>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.